Viridian Therapeutics, Inc. Share Price & Technical Analysis
VRDN · $17.24 (-2.54%)
Healthcare / Biotechnology
$17.24
-2.54%
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develop…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
27% return in May, -7% avg return in past 3 year May month.
-39% return in 2026, 18% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 7% | -10% | -32% | -31% | 27% | – | – | – | – | – | – | – | -39% |
| 25 | -1% | -17% | -13% | 1% | 4% | -1% | 26% | 6% | 17% | 10% | 36% | -2% | 67% |
| 24 | -11% | -4% | -8% | -25% | -11% | 7% | 30% | -13% | 55% | -11% | -1% | -11% | -3% |
| 23 | 24% | -11% | -23% | 10% | -15% | -1% | -21% | -3% | -16% | -19% | 34% | 31% | -10% |
| 22 | 1% | -10% | 4% | -25% | -12% | -6% | 14% | 69% | -7% | -5% | 26% | 15% | 62% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Uptrend
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.73B
P/E ratio
—
52W high
$34.29
52W low
$13.18
Volume
27,99,250
Beta
0.82
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Viridian Therapeutics, Inc. share price today?
- Viridian Therapeutics, Inc. (VRDN) last traded around $17.24 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does VRDN have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for VRDN. Download the app for real-time alerts.
- How can I analyze Viridian Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.